BRAF and melanoma: BRAF inhibition (BRAFi) and combined BRAF/MEK inhibition (BRAFi/MEKi) have shown significant clinical activity in patients with BRAF V600‐mutant advanced melanoma with response rates between 45% and 53% (monotherapy) and 64% and 68% (combination treatment) 1, 2, 3, 4, 5.